Phergain study
WebThe PHERGain study: A.3.2: Name or abbreviated title of the trial where available: PHERGain: A.4.1: Sponsor's protocol code number: MedOPP096-MO39229: A.7: ... The end of study will be three years from surgery (for cohorts A and B and for cohort C only if surgery is performed), up to three years from randomization of the last patient (for ... WebOct 27, 2024 · The study includes 376 women with a type of breast cancer called HER2-positive breast cancer that can be removed by surgery. In the study, researchers wanted …
Phergain study
Did you know?
WebFeb 1, 2024 · Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2) The safety and scientific … WebJun 19, 2024 · The PHERGAIN study is evaluating the use of positron emission tomography (PET) imaging during neoadjuvant therapy to monitor tumor response in patients with HER2-positive breast cancer. In preliminary results, investigators reported that patients whose PET scan showed positive response to the treatment had pathological complete response.
WebA study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B. ... (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study : Secondary IDs: 2016-002676-27 [EudraCT Number] Study Status. Record Verification: July 2024 : Overall Status: Active, … WebMay 19, 2024 · The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary …
WebMay 20, 2024 · The results of the PHERGain study showed a pCR of 35% among the subgroup of patients with ER+/HER2+ EBC treated with neoadjuvant trastuzumab plus pertuzumab plus endocrine therapy who had a... WebFeb 24, 2024 · PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer. The PHERGain II trial will investigate the treatment …
WebEssais cliniques pour trastuzumab emtansin. Registre des essais cliniques. ICH GCP.
WebFeb 3, 2024 · PHERGain-2: a study of a new therapeutic strategy to avoid chemotherapy in breast cancer patients. Updated: Dec 7, 2024. We have initiated the PHERGain-2 clinical … charles starks nc mylife.comWebOct 27, 2024 · The PHERGain study is still ongoing and results on long-term survival are expected to be released in 2024. Clinical Trial Registration: NCT03161353 ( … harry tompkins rodeoWebFeb 1, 2024 · Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms ... (PHERGAIN-2) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. charles starks music city centerWebAbstract. Disrupted protein folding or decreased protein stability can lead to the accumulation of (partially) un- or misfolded proteins, which ultimately cause the … harry tompkins outlanderWebOct 27, 2024 · The PHERGain study is still ongoing and results on long-term survival are expected to be released in 2024. Clinical Trial Registration: NCT03161353 … charles state farmWebMay 18, 2024 · PHERGain was a strategy-based study with a unique design. Previous trials of de-escalation strategies in HER2-positive, early-stage breast cancer have highlighted the importance of establishing innovative clinical designs, together with optimal selection of … charles stanley stepping downWebThe PHERGain study, can you speak to that? Erika P. Hamilton (11:47): PHERGain was a very complicated study. Essentially what they did is they used antibody HER2 treatment and dropped the chemotherapy out for some patients, and other patients got chemotherapy with HER2 treatment. harry toffolo you tube